Replimune Group (NASDAQ:REPL) Upgraded at BMO Capital Markets

Replimune Group (NASDAQ:REPL) was upgraded by BMO Capital Markets from an “underperform” rating to an “outperform” rating in a research report issued on Tuesday, MarketBeat reports. The firm presently has a $16.00 target price on the stock. BMO Capital Markets’ price target suggests a potential upside of 42.86% from the company’s current price.

REPL has been the subject of a number of other reports. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Wedbush lifted their price objective on shares of Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a report on Tuesday. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Jefferies Financial Group restated a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, JPMorgan Chase & Co. raised shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price target for the company in a research note on Friday. Two investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Replimune Group presently has an average rating of “Hold” and a consensus price target of $8.12.

Replimune Group Trading Down 3.7%

REPL opened at $11.20 on Tuesday. Replimune Group has a one year low of $1.50 and a one year high of $13.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The stock has a market cap of $924.78 million, a price-to-earnings ratio of -3.26 and a beta of 0.88. The stock’s 50 day moving average price is $6.41 and its 200-day moving average price is $7.29.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, equities analysts forecast that Replimune Group will post -3.39 EPS for the current year.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of REPL. RTW Investments LP boosted its stake in shares of Replimune Group by 11.6% during the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock valued at $69,404,000 after purchasing an additional 744,620 shares in the last quarter. Fcpm Iii Services B.V. raised its stake in Replimune Group by 6.4% in the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after buying an additional 248,672 shares in the last quarter. State Street Corp raised its stake in Replimune Group by 26.3% in the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after buying an additional 768,982 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Replimune Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after buying an additional 9,707 shares during the period. Finally, Braidwell LP lifted its holdings in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.